Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Astrocytoma 8Glioblastoma 5Prostatic Neoplasms 4Neuroectodermal Tumors, Primitive 4Lymphoma, Non-Hodgkin 4Recurrence 3Lung Neoplasms 3Glioma 3Breast Neoplasms 3Oligodendroglioma 2Neurocytoma 2Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Pituitary Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 34Whole-Body Irradiation 33Bortezomib 33ibrutinib 29Dexamethasone 27Tacrolimus 26Cyclosporine 25Busulfan 23Etoposide 22Melphalan 20Filgrastim 20zanubrutinib 18Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Flow Cytometry 10Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Indium 9Cyclosporins 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × antineoplaston A10 × Clear all
NCT00003512 2018-02-05

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Burzynski Research Institute

Phase 2 Withdrawn
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡